Orthofix International (OFIX) Stock Forecast & Price Target

Orthofix Medical is a medical device company with a solid fourth quarter performance, exceeding expectations in terms of revenue, free cash flow, and adjusted EBITDA. However, guidance for 2026 and 2027 was disappointing, with recalibrated longer-term guidance pushing back the mid-teen adjusted EBITDA margin target to 2028. Gross margin was slightly below expectations and cash flow was positive for the quarter, with strong top line performance in global spine, US limb reconstruction, and bone growth therapies. The company's spinal segment generated $113.6 million in revenue, with $1.3 million from discontinued M6 product lines.

Orthofix Medical is a medical device company that generates the majority of its revenue from its Global Spine segment. However, the company recently reduced its FY/26 revenue and adjusted EBITDA guidance and no longer expects to generate positive free cash flow in FY/26. While the company has solid earnings and FCF growth in its Q4 report, its longer-term financial targets have been pushed back, and it faces ongoing litigation and investigation costs that could negatively impact its profitability. As a result, the financial analyst has a negative outlook on Orthofix Medical's stock, with a recommendation to maintain an OUTPERFORM rating but with a reduced price target of $17.